FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282016274> ?p ?o ?g. }

• W4282016274 endingPage "e2214321" @default.
• W4282016274 startingPage "e2214321" @default.
• W4282016274 abstract "Only about half of patients with atrial fibrillation (AF) who are at increased risk for stroke are treated with an oral anticoagulant (OAC), despite guideline recommendations for their use. Educating patients with AF about prevention of stroke with OACs may enable them as agents of change to initiate OAC treatment.To determine whether an educational intervention directed to patients and their clinicians stimulates the use of OACs in patients with AF who are not receiving OACs.The Implementation of a Randomized Controlled Trial to Improve Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation (IMPACT-AFib) trial was a prospective, multicenter, open-label, pragmatic randomized clinical trial conducted from September 25, 2017, to May 1, 2019, embedded in health plans that participate in the US Food and Drug Administration's Sentinel System. It used the distributed database comprising health plan members to identify eligible patients, their clinicians, and outcomes. IMPACT-AFib enrolled patients with AF, a CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age 65-74 [1 point] or ≥75 years [2 points], diabetes, and stroke, transient ischemic attack or thromboembolism [2 points]-vascular disease, and sex category [female]) score of 2 or more, no evidence of OAC prescription dispensing in the preceding 12 months, and no hospitalization-related bleeding event within the prior 6 months.Randomization to a single mailing of patient and/or clinician educational materials vs control.Analysis was performed on a modified intention-to-treat basis. The primary end point was the proportion of patients with at least 1 OAC prescription dispensed or at least 4 international normalized ratio test results within 1 year of the intervention.Among 47 333 patients, there were 24 909 men (52.6%), the mean (SD) age was 77.9 (9.7) years, mean (SD) CHA2DS2-VASc score was 4.5 (1.7), 22 404 patients (47.3%) had an ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) bleeding risk score of 5 or more, and 8890 patients (18.8%) had a history of hospitalization for bleeding. There were 2328 of 23 546 patients (9.9%) in the intervention group with initiation of OAC at 1 year compared with 2330 of 23 787 patients (9.8%) in the control group (adjusted OR, 1.01 [95% CI, 0.95-1.07]; P = .79).Among a large population with AF with a guideline indication for OACs for stroke prevention who were randomized to a mailed educational intervention or to usual care, there was no clinically meaningful, numerical, or statistically significant difference in rates of OAC initiation. More-intensive interventions are needed to try and address the public health issue of underuse of anticoagulation for stroke prevention among patients with AF.ClinicalTrials.gov Identifier: NCT03259373." @default.
• W4282016274 created "2022-06-13" @default.
• W4282016274 creator A5002314406 @default.
• W4282016274 creator A5006504588 @default.
• W4282016274 creator A5007197817 @default.
• W4282016274 creator A5007502154 @default.
• W4282016274 creator A5011063026 @default.
• W4282016274 creator A5012148455 @default.
• W4282016274 creator A5014449865 @default.
• W4282016274 creator A5014967450 @default.
• W4282016274 creator A5019852114 @default.
• W4282016274 creator A5020320270 @default.
• W4282016274 creator A5023622250 @default.
• W4282016274 creator A5034848641 @default.
• W4282016274 creator A5036080923 @default.
• W4282016274 creator A5038292204 @default.
• W4282016274 creator A5048976344 @default.
• W4282016274 creator A5052527632 @default.
• W4282016274 creator A5056545888 @default.
• W4282016274 creator A5057514738 @default.
• W4282016274 creator A5061084605 @default.
• W4282016274 creator A5066957107 @default.
• W4282016274 creator A5070387023 @default.
• W4282016274 creator A5074889968 @default.
• W4282016274 creator A5077422694 @default.
• W4282016274 creator A5078084167 @default.
• W4282016274 creator A5084326780 @default.
• W4282016274 creator A5091614969 @default.
• W4282016274 date "2022-05-31" @default.
• W4282016274 modified "2023-09-27" @default.
• W4282016274 title "Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants" @default.
• W4282016274 cites W1967046500 @default.
• W4282016274 cites W1980550338 @default.
• W4282016274 cites W1986637035 @default.
• W4282016274 cites W1999468381 @default.
• W4282016274 cites W2000949542 @default.
• W4282016274 cites W2018003197 @default.
• W4282016274 cites W2087435181 @default.
• W4282016274 cites W2087736674 @default.
• W4282016274 cites W2098240323 @default.
• W4282016274 cites W2105981676 @default.
• W4282016274 cites W2129471004 @default.
• W4282016274 cites W2131216658 @default.
• W4282016274 cites W2135694398 @default.
• W4282016274 cites W2141889414 @default.
• W4282016274 cites W2152623033 @default.
• W4282016274 cites W2298220628 @default.
• W4282016274 cites W2375143166 @default.
• W4282016274 cites W2581246531 @default.
• W4282016274 cites W2603057432 @default.
• W4282016274 cites W2616300024 @default.
• W4282016274 cites W2750530717 @default.
• W4282016274 cites W2765138321 @default.
• W4282016274 cites W2886291731 @default.
• W4282016274 cites W2901894544 @default.
• W4282016274 cites W2912169711 @default.
• W4282016274 cites W2922726768 @default.
• W4282016274 cites W2954534472 @default.
• W4282016274 cites W2957544571 @default.
• W4282016274 cites W2969408451 @default.
• W4282016274 cites W3013924214 @default.
• W4282016274 cites W3037230892 @default.
• W4282016274 cites W3045328587 @default.
• W4282016274 cites W3082188176 @default.
• W4282016274 cites W4200044943 @default.
• W4282016274 cites W4205725164 @default.
• W4282016274 cites W4233664165 @default.
• W4282016274 cites W4238513077 @default.
• W4282016274 cites W4292280632 @default.
• W4282016274 cites W4297918764 @default.
• W4282016274 cites W59237391 @default.
• W4282016274 doi "https://doi.org/10.1001/jamanetworkopen.2022.14321" @default.
• W4282016274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35639381" @default.
• W4282016274 hasPublicationYear "2022" @default.
• W4282016274 type Work @default.
• W4282016274 citedByCount "4" @default.
• W4282016274 countsByYear W42820162742022 @default.
• W4282016274 countsByYear W42820162742023 @default.
• W4282016274 crossrefType "journal-article" @default.
• W4282016274 hasAuthorship W4282016274A5002314406 @default.
• W4282016274 hasAuthorship W4282016274A5006504588 @default.
• W4282016274 hasAuthorship W4282016274A5007197817 @default.
• W4282016274 hasAuthorship W4282016274A5007502154 @default.
• W4282016274 hasAuthorship W4282016274A5011063026 @default.
• W4282016274 hasAuthorship W4282016274A5012148455 @default.
• W4282016274 hasAuthorship W4282016274A5014449865 @default.
• W4282016274 hasAuthorship W4282016274A5014967450 @default.
• W4282016274 hasAuthorship W4282016274A5019852114 @default.
• W4282016274 hasAuthorship W4282016274A5020320270 @default.
• W4282016274 hasAuthorship W4282016274A5023622250 @default.
• W4282016274 hasAuthorship W4282016274A5034848641 @default.
• W4282016274 hasAuthorship W4282016274A5036080923 @default.
• W4282016274 hasAuthorship W4282016274A5038292204 @default.
• W4282016274 hasAuthorship W4282016274A5048976344 @default.
• W4282016274 hasAuthorship W4282016274A5052527632 @default.
• W4282016274 hasAuthorship W4282016274A5056545888 @default.
• W4282016274 hasAuthorship W4282016274A5057514738 @default.
• W4282016274 hasAuthorship W4282016274A5061084605 @default.

• next